X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/02/2874183/0/en/STALICLA-initiates-U-S-Phase-3-enabling-DDI-study-of-STP7-Mavoglurant-to-treat-cocaine-use-disorder.html
https://www.globenewswire.com//news-release/2024/01/16/2809634/0/en/Stalicla-Secures-17-4-Million-in-Series-B-Financing-to-Propel-Precision-Neuro-Advancements.html
https://www.globenewswire.com/news-release/2023/03/27/2634637/0/en/STALICLA-and-Firefly-Neuroscience-enter-Partnership-Agreement-for-the-Development-of-Electroencephalogram-EEG-as-a-Biomarker-for-Subgroups-of-Patients-with-ASD.html
https://www.globenewswire.com/news-release/2023/03/08/2622807/0/en/STALICLA-signs-Cooperative-Research-and-Development-Agreement-CRADA-with-US-National-Institute-on-Drug-Abuse-NIDA-to-cover-Phase-3-development-of-mavoglurant-in-cocaine-use-disorde.html
https://www.fiercebiotech.com/biotech/stalicla-pledges-270m-take-forward-novartis-failed-fragile-x-candidate#:~:text=Stalicla%20pledges%20%24270M%20to,failed%20former%20fragile%20X%20candidate&text=Novartis%20has%20kept%20the%20faith,the%20asset%20into%20phase%203.
https://www.globenewswire.com/news-release/2023/01/09/2584796/0/en/STALICLA-signs-exclusive-in-licensing-agreement-for-late-stage-clinical-neuropsychiatric-and-neurodevelopmental-disorder-treatment.html
Market Place
Share 
